RNA Analysis Market Size, Share, Opportunities, And Trends By Product (Instruments, Kits & Reagents, Services), By Technology (Real-Time PCR, Microarray, Sequencing, Others), By End-Use (Hospitals, Clinics, Others), And By Geography - Forecasts From 2023 To 2028

The RNA analysis market is estimated to grow at a CAGR of 3.48% during the forecast period.

RNA analysis is a broad term that encompasses various techniques and methods used to study RNA molecules within a biological sample. RNA (ribonucleic acid) is a fundamental molecule involved in gene expression, protein synthesis, and regulation of cellular processes. The rising incidence of cancer and infectious diseases and the valuable application of RNA analysis in these diseases is a major growth driver of the RNA analysis market. Moreover, the increasing adoption of personalized medication along with the numerous research studies and developments to improve the RNA-based solutions are further accelerating the RNA analysis market growth.

Rising Prevalence of Cancer

RNA analysis has played a significant role in advancing cancer research and understanding the molecular mechanisms underlying cancer development and progression. The rising cancer cases are therefore a major growth driver of the RNA analysis market. For instance, cancer is the major leading cause of death worldwide which amounted to 10 million deaths in 2020 as per the WHO. According to the World Cancer Research Fund, there were an estimated 18.1 million new cancer cases worldwide. There were 8.8 million cases in women and 9.3 million in males. RNA analysis, especially through RNA-sequencing has been crucial in the discovery of novel fusion genes and understanding their role in various cancer types.

Growing Burden of Infectious Diseases

The RNA analysis market is widening due to the rising number of infectious diseases around the globe. The study of RNA in infectious disease research provides valuable information about the genetic makeup of pathogens, their virulence factors, and how they interact with the host immune system. For instance, around 39 million people were living with HIV worldwide in 2022 as per the WHO data. HIV-related deaths accounted for 630,000 deaths in 2022, and 1.3 million persons contracted the virus. Further, over 265,159 samples were evaluated by the WHO GISRS laboratories throughout the two weeks in June 2023.

Increasing Emphasis on Personalized Medicine

The study of RNA in cancer research has allowed for the identification of cancer-specific gene expression patterns and potential biomarkers for early diagnosis and personalized treatment. There are numerous ongoing research to develop more targeted treatments for the treatment of cancer using RNA which is expected to boost the RNA analysis market. For example, Moderna Inc. and Merck announced that the U.S. Food and Drug Administration (FDA) had designated mRNA-4157/V940 investigational personalized mRNA cancer vaccine as a breakthrough therapy for the adjuvant treatment of patients with high-risk melanoma after complete resection.

Biopharmaceutical Research and Development

In the pharmaceutical industry, RNA analysis is crucial for drug discovery, target identification, and biomarker research. The increasing development of RNA-based therapeutics, such as mRNA vaccines and RNA interference (RNAi) therapies is also driving the RNA analysis market. For instance, between 2010 and 2019, there was a 60 percent increase in the number of new drugs approved for sale compared to the previous decade in the US according to the Congressional Budget Office. The AlphaFold2 AI technology from DeepMind significantly improved human understanding of biology. With that development, Alphabet launched Isomorphic Labs in 2021 which was a brand-new business specializing in AI-driven medication discovery.

Increasing Research and Government Initiative

The increasing research projects and government initiatives for medical study and enhanced treatment using RNA are contemplated to aid the RNA analysis market. For instance, new research by the University of Innsbruck developed a new method to study the binding of aminoglycoside Neomycin B to a so-called mRNA riboswitch in July 2023. Additionally, research by the University of Otago began in July 2023 to improve RNA diagnostics to provide more certainty for genetic testing. It aims to examine how changes to DNA affect a similar molecule RNA. Moreover, the inauguration of the Darlington RNA vaccine innovation facility was supported by an extra £10.65 million in funding from the UK government's Vaccine Taskforce in October 2022.

North America is Expected to Grow Significantly

North America is expected to hold a significant share of the RNA analysis market during the forecast period. The factors attributed to such a share are the rising number of cancer cases, infectious diseases, government support, technological advancements, and multiple research studies. For instance, according to National Cancer Institute estimates, around 1.8 million new cases of cancer were identified in the US year 2020 and 606,520 individuals died from the illness. The majority of cancer cases (1,117,640) occurred among adults 65 and older, more than any other age group. The elderly population aged 65 years or above is continuously rising in the region which is further increasing the demand for RNA analysis.

Major Market Players

• Promega Corporation is a global biotechnology company that specializes in providing innovative solutions for life sciences research, drug discovery, clinical diagnostics, and applied fields. Standalone reverse transcriptases (AMV, M-MLV, and GoScript) and a variety of full kits with enzymes, buffers, and reagents are available as Promega RT-PCR products.
• Lexogen was founded in 2007 with a primary focus to provide products and services that enable researchers to study RNA molecules in various biological samples and contexts. It offers CORALL RNA-Seq Library Prep kits, LUTHOR 3’ mRNA-Seq Library kits, and several other ranges of RNA products.
• Zymo Research Corporation is a US-based biotechnology company.  It specializes in providing research tools and services for epigenetics, nucleic acid purification, and microbiomics. It offers a total of 52 RNA-related kits including Direct-zol RNA Microprep kits and Direct-zol-96 RNA kits.

Key Market Developments

• In May 2023, Twist Bioscience Corporation launched a portfolio of RNA sequencing tools which includes Twist RNA Exome, Twist RNA Library Prep Kit, and Twist Ribosomal RNA & Hemoglobin Depletion Kit. This comprehensive kit of RNA tools enables transcriptome research across fields such as precision medicine, biomarker discovery, and immune-oncology research.
• In June 2022, Fluent BioSciences introduced two ground-breaking PIPseq T2 and T20 v3.0 kits for three ′ single-cell RNA analysis. These may, respectively, catch up to 2,000 and 20,000 individual cells or nuclei in each reaction.
• In March 2021, Rebus Biosystems introduced the Rebus Esper, a platform for spatial transcriptomics investigation of the transcriptome. This device enables researchers to study individual cells and produces high-resolution pictures using laser-powered optics.

RNA Analysis Market Scope:

Segmentation:

• By Product
  • Instruments
  • Kits & Reagents
  • Services
• By Technology
  • Real-Time PCR
  • Microarray
  • Sequencing
  • Others
• By End-Use
  • Hospitals
  • Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others